Jeffrey Schleich, MD
Family Medicine · Freeport, ILNPI 1215900519
Payments from drug & device makers
Across 507 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Merck$768
- GSK$691
- Novo Nordisk$575
- Boehringer Ingelheim$547
- Lilly USA, LLC$347
- plus $4K from 28 others
What the payments were for
- Food & beverage$7,864100%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $1,306 |
| Merck | 51 | $768 |
| GSK | 52 | $691 |
| Novo Nordisk | 43 | $575 |
| Boehringer Ingelheim | 38 | $547 |
| Lilly USA, LLC | 31 | $347 |
| Johnson & Johnson | 25 | $332 |
| Amgen(2 entities) | 22 | $324 |
| Pfizer | 19 | $314 |
| E.r. Squibb & Sons, L.L.C. | 17 | $277 |
| AbbVie | 18 | $258 |
| Sanofi-aventis U.S. LLC | 12 | $229 |
| Sumitomo Pharma America, Inc. | 10 | $220 |
| Kowa Pharmaceuticals America, Inc. | 14 | $205 |
| Astellas Pharma US Inc | 10 | $192 |
| Bayer | 10 | $167 |
| Otsuka America Pharmaceutical, Inc. | 8 | $155 |
| Novartis | 11 | $148 |
| Exact Sciences | 6 | $121 |
| Mylan Specialty L.p. | 6 | $105 |
| Amarin Pharma, Inc. | 6 | $93 |
| Corcept Therapeutics | 5 | $90 |
| Sunovion Pharmaceuticals Inc. | 7 | $89 |
| Abbott | 5 | $78 |
| Dexcom, Inc. | 4 | $52 |
| Eisai Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Biodelivery Sciences International, Inc. | 2 | $24 |
| Verona Pharma, Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $13 |
How this compares
$7,900 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 257 | $277,379 |
| FarxigaDapagliflozin Propanediol | 215 | $236,586 |
| EliquisApixaban | 332 | $225,421 |
| OzempicSemaglutide | 150 | $191,096 |
| JardianceEmpagliflozin | 117 | $147,984 |
| MounjaroTirzepatide | 134 | $144,482 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 101 | $137,959 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $119,541 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $79,602 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 63 | $76,108 |
| RybelsusSemaglutide | 30 | $61,240 |
| TrulicityDulaglutide | 35 | $58,071 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $39,685 |
| GemtesaVibegron | 57 | $37,038 |
| MyrbetriqMirabegron | 45 | $35,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Fiasp | $575 | $397,333293 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,306 | $283,194276 claims |
| Johnson & JohnsonXarelto | $332 | $277,379257 claims |
| PfizerEliquis, Abrysvo, Paxlovid | $314 | $241,161377 claims |
| Lilly USA, LLCMounjaro, Trulicity | $347 | $202,553169 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $547 | $167,610144 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $691 | $155,470189 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $229 | $76,10863 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $220 | $37,03857 claims |
| Astellas Pharma US IncMyrbetriq | $192 | $35,72245 claims |
| MerckJanuvia | $768 | $33,32944 claims |
| NovartisEntresto | $148 | $20,83318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Freeport
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.